Irish Dermatologists' Experience with Janus Kinase Inhibitors in Alopecia Areata

A study involving 21 Irish dermatologists (17% response rate) explored their experiences with Janus kinase inhibitors (JAKis) in treating alopecia areata (AA). The majority (90%) had used JAKis, primarily baricitinib (81%), and assessed treatment response at 3 or 6 months. Factors influencing JAKi use included the patient's Dermatology Life Quality Index, age, comorbidities, literature on long-term effects, and cost reimbursement. There is significant variability in ongoing treatment practices, with 95% of respondents highlighting the urgent need for guidelines on JAKi use in AA due to the lack of clear literature and global guidelines.